KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial.

Susan Abushakra, Aidan Power, David Watson, Anton Porsteinsson, Marwan Sabbagh, Emer MacSweeney, Sharon Cohen, Mercè Boada Rovira, P Murali Doraiswamy, Earvin Liang, Susan Flint, J Patrick Kesslak, Rosalind McLaine, Adem Albayrak, Jean Schaefer, Jeremy Yu, Luke Tolar, Sam Dickson, John A Hey, Martin Tolar

Drugs 85(11) 1455-1472

PMID41015981
PMCIDPMC12572085
DOI10.1007/s40265-025-02250-5
发表日期2025-09-28
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 multi panel km;Fig. 3:AI 判定为 forest plot;Fig. 4:AI 判定为 multi panel km;Fig. 5:AI 判定为 forest plot;另有 1 张未列出。
摘要

摘要

BACKGROUND: The apolipoprotein E ε4 (APOE ε4) allele is the strongest genetic risk factor for Alzheimer's disease (AD), with homozygotes accumulating a high burden of cerebral beta-amyloid (Aβ) pathology. Valiltramiprosate/ALZ-801 is a small-molecule potent inhibitor of Aβ-oligomer formation. The efficacy, safety/tolerability, and brain volume effects of oral valiltramiprosate were evaluated in this phase III, randomized, double-blind, placebo-controlled, multi-center, 78-week trial in homozygotes with early symptomatic AD. METHODS: The study enrolled eligible APOE4/4 subjects aged 50-80 years with Early AD (Mini-Mental State Examination [MMSE] 22-30), which included mild cognitive impairment (MCI) and mild dementia, Clinical Dementia Rating-Global Score (CDR-G) of 0.5 or 1, who were randomized 1:1 to valiltramiprosate (265 mg twice/day) or placebo. The primary outcome was AD Assessment Scale-Cognitive Subscale (ADAS-Cog13); the key secondary outcomes were CDR-Sum of Boxes (CDR-SB) and Amsterdam-Instrumental Activities of Daily Living (IADL), and a secondary outcome was Disability Assessment for Dementia (DAD). The main imaging outcome was hippocampal volume on MRI; diffusion tensor imaging (MRI-DTI) assessed microstructural tissue integrity. Amyloid-related imaging abnormalities (ARIA) were monitored with MRIs every 26 weeks. RESULTS: A total of 325 participants enrolled and received study drug. At 78 weeks, the overall efficacy population did not show significant effects on ADAS-Cog13 or other clinical outcomes compared with placebo (ADAS-Cog13: 11% slowing; p = 0.607, N = 320), but showed significant slowing of hippocampal atrophy (18%, p = 0.017, N = 290). Prespecified analyses by disease severity (stratification variable) showed no significant clinical effects in mild AD (MMSE ≤26, N = 195). The prespecified MCI group (MMSE >26, N = 125) showed nominally significant positive effects on ADAS-Cog13 (52%, nominal p = 0.041) and DAD (96%, nominal p = 0.016), positive trend on CDR-SB (102%, nominal p = 0.053), with significant hippocampal atrophy slowing (26%, p = 0.004), and positive grey/white matter effects on MRI-DTI. In the MCI group, positive ADAS-Cog13 drug effects showed significant subject-level correlations with positive effects on imaging outcomes. The most common adverse events were nausea, vomiting, and decreased appetite (more than double placebo rate), with no increased risk of brain edema or microhemorrhages. CONCLUSIONS: The APOE4/4 Early AD population did not show significant clinical efficacy at 78 weeks but showed significant brain atrophy slowing. Prespecified analyses at the MCI stage showed nominally significant slowing of clinical decline with significant hippocampal atrophy slowing. Oral valiltramiprosate may provide a favorable benefit-risk profile and simple treatment paradigm for homozygotes with MCI. These results will inform the design of future MCI trials. TRIAL REGISTRATION: Clinicaltrials.gov: NCT04770220; EudraCT Number: 2020-005755-20.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 CONSORT diagram of participant disposition. ALZ-801 valiltramiprosate, APOE apolipoprotein E, FAS full analysis set, Meds medications, MMSE Mini-Mental State Examination, MRI magnetic resonance imaging, PI principal investigator, RBANS Repeatable Battery for the Assessment of Neuropsychological Status, TEAE treatment-emergent adverse event
非 KM Figure
Fig. 2Fig. 2 Effects of ALZ-801/valiltramiprosate on the main clinical outcomes in the overall efficacy population (FAS, full analysis set) and in participants with mild cognitive impairment (MCI). Results shown from a mixed-effect repeated measure model (MMRM); LSM least squares mean. a , e ADAS-Cog13 (13-item Alzheimer’s Disease Assessment Scale—Cognitive Subscale); b , f CDR-SB (Clinical Dementia Rating—Sum of Boxes); c , g DAD (Disability Assessment for Dementia); d , h IADL (Amsterdam—Instrumental Activities of Daily Living weighted average)
非 KM Figure
Fig. 3Fig. 3 Sensitivity analyses of the main clinical outcomes, showing placebo-adjusted point estimates in progressively earlier disease stages by screening MMSE (MMRM analysis). a ADAS-Cog13 (13-item Alzheimer’s Disease Assessment Scale—Cognitive Subscale); b CDR-SB (Clinical Dementia Rating—Sum of Boxes); c DAD (Disability Assessment for Dementia). LS Mean Diff – Wk 78 LSMs of drug–placebo difference at 78 weeks; Estimate: point estimate for the LS means difference; 95% CI 95% confidence interval, N = number of participants at baseline for each MMSE category. The bolded point estimates are ones that show positive trend favoring drug with p < 0.1. Note: MMSE 22–30 is the full analysis set (FAS); MCI is defined as MMSE >26. MCI mild cognitive impairment, MMSE Mini-Mental State Examination, MMRM mixed-effect model repeated measure
非 KM Figure
Fig. 4Fig. 4 Effects of ALZ-801/valiltramiprosate on volumetric outcomes in the overall imaging population (FAS, imaging population full analysis set) and in participants with mild cognitive impairment (MCI, imaging population). Results shown from a mixed-effect repeated measure model (MMRM); LSM least squares mean. Note: increase in ventricular volume (expansion) indicates brain atrophy
非 KM Figure
Fig. 5Fig. 5 Effects of ALZ-801/valiltramiprosate on the main DTI endpoints in participants with mild cognitive impairment (MCI). Results shown from a mixed-effect repeated measure model (MMRM) in the DTI population. a Grey matter regions, b white matter tracts. DTI diffusion tensor imaging, a measure of mean extracellular water diffusivity in brain tissue, where lower diffusivity indicates positive drug effect, LSM least squares mean, N number of participants in DTI population
非 KM Figure
Fig. 6Fig. 6 Pearson’s correlations of clinical outcomes with HV, DTI, and plasma biomarker outcomes in MCI group (observed case analysis). The correlations represent Pearson’s correlations of changes from baseline to 78 weeks. Correlation of +1 indicates the strongest positive relationship, −1 indicates the strongest negative relationship and 0 indicates no linear relationship. In AD trials, correlations between 0.2 and 0.29 are considered modest, between 0.30 and 0.39 are moderate strength, and ≥0.40 are considered strong correlations. The noted ADAS, CDR and HV correlations to DTI outcomes were to the frontal cortex (grey matter). The noted HV correlation to DTI outcome was to the genu of corpus callosum (white matter tract). ADAS Alzheimer’s Disease Assessment Scale—Cognitive Subscale, CDR-SB Clinical Dementia Rating—Sum of Boxes, DTI diffusion tensor imaging, mean diffusivity, HV hippocampal volume, MCI mild cognitive impairment, NfL plasma level of neurofilament light chain
非 KM Figure